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A B S T R A C T
Objectives: Chronic necrotizing pulmonary aspergillosis (CNPA) is uncommon, and the optimal
therapeutic regimen has not been established. In a retrospective cohort study, we investigated the
clinical characteristics and treatment outcomes of patients with CNPA.
Methods: We reviewed the medical records of all patients who had been diagnosed with CNPA at our
institution over the last 10 years.
Results: Forty-three patients were identiﬁed. Their median age was 60 years (interquartile range (IQR)
45–65 years), and 34 (79%) of the patients were men. The most common underlying lung disease was
pulmonary tuberculosis (n = 40, 93%). After CNPA was diagnosed, all patients were treated with
antifungal drugs, including oral itraconazole (n = 39, 91%) or intravenous amphotericin B (n = 4, 9%).
Seventeen (40%) patients discontinued therapy early (<3months), 14 patients due to death and three to
loss of follow-up. Twenty-six (60%) patients received oral itraconazole at a daily dose of 200–400 mg for
more than 3 months. The median treatment duration was 6 months (IQR 6–12 months). In these 26
patients, clinical improvement was observed in 15 (58%) and radiological improvement was observed in
11 (42%). Ten (38%) patients showed no improvement. Twenty-two (51%) patients died, including 18
(42%) CNPA-related deaths, during a median follow-up of 15 months (IQR 2.5–32 months). The median
survival time was 62 months.
Conclusions: CNPA is difﬁcult to treat and often has a poor outcome. Further studies with more patients
are needed to identify the optimal therapy for patients with CNPA.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In the early 1980s, chronic necrotizing pulmonary aspergillosis
(CNPA), also called semi-invasive or subacute invasive pulmonary
aspergillosis, was ﬁrst described as a distinct type of pulmonary
aspergillosis.1,2 CNPA was described as an indolent, cavitary,
infectious process of the lung parenchyma secondary to local
invasion by Aspergillus species, usually Aspergillus fumigatus. CNPA
tends to affect persons with abnormal pulmonary defense
mechanisms as a result of underlying lung disease or immuno-
compromise.3
Conﬁrmation of the diagnosis requires histological demonstra-
tion of tissue invasion by the fungus and the growth of Aspergillus
species on culture.2,4,5 However, the yield of transbronchial biopsy
specimens or percutaneous aspirates is relatively poor, and a
surgical biopsy is rarely performed in these patients because of* Corresponding author. Tel.: +82 2 3410 3429; fax: +82 2 3410 6956.
E-mail address: wjkoh@skku.edu (W.-J. Koh).
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doi:10.1016/j.ijid.2009.07.011impaired respiratory function or the severity of the comorbidity.
Consequently, conﬁrmation of the diagnosis is difﬁcult, and a
delayed diagnosis is common. Establishing a diagnosis requires a
combination of clinical, radiological, and laboratory ﬁndings.6 Case
reports and small retrospective case series have documented
variable treatment outcomes in CNPA patients managed with
antifungal agents.4,7–10
CNPA is uncommon, and the optimal therapeutic regimen and
treatment duration have not been established. Therefore, we
conducted a retrospective cohort study of patients who had been
diagnosed with CNPA at out institution over the last 10 years to
investigate the clinical characteristics and treatment outcomes of
patients with CNPA.
2. Patients and methods
2.1. Patients
We reviewed the medical records of all patients who had
positive serum precipitating antibodies to Aspergillus fumigatus orses. Published by Elsevier Ltd. All rights reserved.
Table 1
Diagnostic criteria for chronic necrotizing pulmonary aspergillosisa
Diagnostic criteria Characteristics
Clinical Chronic pulmonary or systemic symptoms (>1 month), including at least one of weight loss, productive cough, or hemoptysis
No overt immunocompromising conditions (e.g., hematological malignancy, neutropenia, organ transplantation)
No dissemination
Radiological Cavitary pulmonary lesion with evidence of paracavitary inﬁltrates
New cavity formation, or expansion of cavity size over time
Laboratory Elevated levels of inﬂammatory markers (C-reactive protein or erythrocyte sedimentation rate)
Either a positive serum Aspergillus precipitin test or isolation of Aspergillus spp from the pulmonary or pleural cavity
Exclusion of other pulmonary pathogens with similar disease presentation, including mycobacteria and endemic fungi,
using appropriate cultures and serological tests
a Modiﬁed from references 3 and 6.
Table 2
Patient characteristics
Characteristics Number (%) or median (IQR)
Age, years 60 (45–65)
Sex, male 34 (79%)
Body mass index (kg/m2) 17.5 (15.1–19.6)
Underlying lung disease 41 (95%)
Previous mycobacterial disease 40 (93%)
Previous thoracic surgery 9 (21%)
Chronic obstructive pulmonary disease 6 (14%)
History of pneumothorax 3 (7%)
Pneumoconiosis 1 (2%)
Idiopathic pulmonary ﬁbrosis 1 (2%)
Systemic illnesses 17 (40%)
Previous corticosteroid use 8 (19%)
Diabetes mellitus 5 (12%)
Chronic liver disease 4 (9%)
Connective tissue disease 3 (7%)
Malignancya 2 (5%)
IQR, interquartile range.
a Malignancy includes lung cancer (n=1) and advanced gastric cancer (n=1).
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January 1995 and December 2007 at Samsung Medical Center, a
1250-bed referral hospital in Seoul, South Korea.
The diagnosis of CNPA was considered certain when it was
associated with the following: (1) compatible symptoms; (2)
compatible chest imagery ﬁndings; and (3) a positive serum
Aspergillus precipitin test or positive isolation of Aspergillus
species from a respiratory sample (i.e., sputum, transtracheal
aspirate, or bronchial aspiration ﬂuid) (Table 1).3,6,11
2.2. Data collection
The following data were collected: clinical characteristics,
treatment modalities for the underlying lung disease, chest
radiography and computed tomography (CT), laboratory data,
including the erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP), and the treatment outcome. Datawere collected on a
standardized, anonymous form. Last follow-up data were collected
on August 31, 2008. The Institutional Review Board at Samsung
Medical Center approved the study protocol. Informed consentwas
waived because of the retrospective nature of the study.
2.3. Treatment outcomes and survival
Clinical improvementwas deﬁned as the disappearance ofmore
than half of the symptoms noted at the initial evaluation during
follow-up visits. Radiological improvement was deﬁned as the
partial or complete disappearance of ﬁndings initially considered
to be related to CNPA, although abnormalities related to the lung
disease that contributed to the development of CNPA could persist.
For survival analysis, time zero was deﬁned as the date of
diagnosis of CNPA. Cumulative survival probabilities were
estimated using the Kaplan–Meier method. The most recent
information on patient survivalwas obtained frommedical records
or by searching the national death registry of the Korea National
Statistics Ofﬁce as of August 31, 2008.
3. Results
3.1. Patient characteristics
Forty-three patients were included in this study. Their median
age was 60 years (interquartile range (IQR) 45–65 years). Thirty-
four (79%) of the patients were men and nine were women. Ten
(23%) patients were current smokers and 13 (30%) were ex-
smokers.
Forty-one (95%) patients had at least one underlying lung
disease. The most common underlying lung disease was previous
pulmonary tuberculosis, which had occurred in 40 (93%) patients,
ﬁve of whom also had a history of non-tuberculous mycobacterial
lung disease. Nine (21%) patients had undergone thoracic surgery
for an aspergilloma (n = 3), mycobacterial disease (n = 2), lungcancer (n = 1), pneumothorax (n = 2), or chronic empyema (n = 1).
Seventeen (40%) patients had underlying systemic illnesses,
including a history of oral corticosteroid use (n = 8) and diabetes
mellitus (n = 5) (Table 2).
At the time of diagnosis, all patients presented with at least one
of the following symptoms: productive cough (n = 45, 100%),
hemoptysis (n = 21, 49%), weight loss (n = 15, 35%), and fever (n = 9,
21%). Themedian duration from the onset of symptoms to the time
of diagnosis was 6 months (IQR 2–18 months).
3.2. Chest CT ﬁndings
Chest CT at the time of diagnosis was available for all patients.
The most frequent CT abnormalities were a cavity or cavities in 43
(100%) patients, parenchymal consolidation surrounding the
cavity (or cavities) in 36 (84%), pleural thickening in 35 (81%),
and a mycetoma, which was an intracavitary mass separated from
the surrounding wall by a crescent of air, in 21 (49%) (Table 3).
Three or more of these CT abnormalities were found in 34 (79%)
patients (Figure 1). The most frequent locations of the chest CT
abnormalities were the left upper lobe (n = 18, 42%) and right
upper lobe (n = 14, 33%).
3.3. Laboratory ﬁndings
Serum Aspergillus precipitin antibody tests were performed in
30 patients, 29 (97%) ofwhomhad positive results. Fungus cultures
from respiratory specimens were performed in 42 patients, and 34
(81%) had positive cultures: Aspergillus fumigatus in 31, Aspergillus
niger in three, and Aspergillus ﬂavus in one. Two Aspergillus species
were isolated from one patient. CRP levels (normal range 0–
Table 3
Chest computed tomography ﬁndings
Characteristics Number (%)
Cavity (or cavities) 43 (100%)
Parenchymal consolidation 36 (84%)
Pleural thickening 35 (81%)
Fungus ball (mycetoma) 21 (49%)
Bronchiectasis 16 (37%)
Bronchopulmonary ﬁstula 8 (19%)
Emphysema 6 (14%)
Table 4
Treatment responses of 26 patients who received oral itraconazole for more than 3
months
Treatment response Number (%)
Clinical improvement 15/26 (58%)
Radiological improvement 11/26 (42%)
Clinico-radiological improvement 10/26 (38%)
No improvement 10/26 (38%)
Mycologic negative conversion 10/14 (71%)
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13.0 mg/dl), and the ESR (normal range 0–22 mm/h) was elevated,
with a median of 82 mm/h (IQR 52–112.0 mm/h).
3.4. Treatments and outcomes
In 15 (35%) patients, pulmonary tuberculosis was initially
suspected, and empirical anti-tuberculosis treatment was admi-
nistered. However, no mycobacteria were isolated in repeated
culture examinations, and neither symptoms nor the chest
radiographic ﬁndings improved.
After a diagnosis of CNPA, all patients were treated with
antifungal drugs, including oral itraconazole (n = 39, 91%) or
intravenous amphotericin B (n = 4, 9%). Seventeen (40%) patients
discontinued therapy early (<3 months), 14 patients due to death
and three due to loss of follow-up. The median duration of
treatment in these 17 patients was 1 month (IQR 1–2 months). All
four patients who started amphotericin B therapy for severe
disease died. The causes of death in the 14 patients were
progression of CNPA (n = 12), complication of surgery for CNPA
(n = 1), and infective endocarditis (n = 1).Figure 1. Chest computed tomography of a 46-year-old man with chronic
necrotizing pulmonary aspergillosis and a history of pulmonary tuberculosis. (A) CT
scan obtained with lung windows shows a large cavity in the right upper lobe with
surrounding parenchymal consolidation. Also note lobular consolidation in the left
upper lobe. (B) CT scan obtained with mediastinal windows shows the low-
attenuation soft tissue (white arrow) in the cavity, which suggests aspergilloma.
Pleural thickening (black arrowhead) is also seen.Oral itraconazole at a daily dose of 200–400 mg was
administered for more than 3 months in 26 (60%) patients. The
median duration of treatment was 6 months (IQR 6–12 months).
Clinical improvement was observed in 15 (58%) patients and
radiological improvement was observed in 11 (42%). Ten (38%)
patients showed no improvement (Table 4).
Three patients underwent combined surgical treatment. One
patient underwent a pneumonectomy for massive hemoptysis
after 1 month of amphotericin B therapy. In two patients,
lobectomies were performed for persistent hemoptysis, despite
6- or 10-month therapy with oral itraconazole. All three patients
died of postoperative complications within 1 month of surgery.
As mentioned above, death occurred during the initial
treatment in 14 patients, and eight additional deaths occurred
during follow-up. The median follow-up duration from disease
diagnosis to either death or closing date was 15 months (IQR 2.5–
32 months) for all patients. Twenty-two (51%) patients died, with
18 (42%) CNPA-related deaths. The median survival time was 62
months (Figure 2).
4. Discussion
This study investigated the clinical characteristics and
treatment outcome of 43 patients with CNPA. The most
important ﬁnding of our study is the poor prognosis of these
patients despite antifungal treatment, mainly oral itraconazole.
Itraconazole therapy was continued for more than 3 months in
only 60% (26/43) of the patients, because of the high early
mortality rate. Moreover, in these 26 patients, clinical or
radiological improvement was observed in only about 60%.
Fifty percent of all patients died, and the median survival time
was only 62 months.
CNPA usually occurs in middle-aged and elderly patients with
underlying chronic lung diseases, such as old tuberculosis, chronic
obstructive pulmonary disease, pneumoconiosis, or thoracic
surgery. CNPA is more likely to develop if the previous anatomical
alteration has progressed, such as with inactive tuberculosis withFigure 2. Kaplan–Meier plot of survival probability from the time of the diagnosis of
chronic necrotizing pulmonary aspergillosis in all patients (N = 43). The median
survival time was 62 months.
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cough, and weight loss of 1 to 6 months duration.12 The
radiographic ﬁndings show progressive upper lobe cavitary
inﬁltrates associated with pleural thickening. Aspergillomas are
seen in about 50% of the patients.13
In our study, the diagnosis of CNPA was made using
recommended diagnostic criteria.3,6,11 In our series, the median
age of the patients was 60 years. The most common underlying
pulmonary disorders were sequelae of pulmonary tuberculosis in
93% (40/43) of the patients, and 21% (9/43) had undergone
previous thoracic surgery. All patients presented with a chronic
productive cough, hemoptysis, weight loss, or fever.More than 95%
of the patients were positive for Aspergillus antibody, and 81% of
them were culture-positive for Aspergillus. These cases do not
differ greatly in their clinical features from those reported
elsewhere.1,2,6,12–16
Antifungal therapy is the treatment mainstay for patients
diagnosed with CNPA. Although initial reports advocated intrave-
nous amphotericin B, itraconazole is now regarded as a better
initial therapy because of its efﬁcacy and minimal toxicity.13 The
Infectious Diseases Society of America (IDSA) recommends the use
of oral itraconazole for the treatment of CNPA.17 However, the
treatment outcomes have varied among studies, and data on the
long-term survival of patients with CNPA are still scarce.
Most clinical experiencewith the use of itraconazole is based on
European studies, which have reported good responses with
itraconazole; improvement or cure was described in 90% of the
patients treated.8,18 In the series by Dupont,8 14 patients were
treatedwith itraconazole for 2 to 7months: eight (57%)were cured
and ﬁve were stabilized. They reported no deaths during a follow-
up period averaging 11 months; however, only three of these
patients had long-term follow-up (from 24 to 36 months).
Likewise, in the series by De Beule et al.,18 marked improvement
or cure was observed in 66% (29/44) of CNPA patients. Itraconazole
treatment time ranged from less than 1 month to more than 18
months. However, itraconazole may be a suppressive, rather than
curative, therapy in CNPA. Caras and Pluss4 reported residual CNPA
in pathology specimens obtained at the time of surgery or autopsy,
despite 5 to 12 months of treatment, and even though the patients
experienced initial clinical improvement.
We observed clinical or radiological improvement in only 38%
(10/26) of the patients who were treated with itraconazole for
more than 3 months. Furthermore, there were no clinical or
radiological improvements in 38% (10/26) of the patients, despite a
6-month median duration of itraconazole treatment.
The reported mortality of CNPA varies widely and may be
limited by incomplete follow-up. Mortality is as high as about 40%
in American experiences,1,2,4,13 but is less than 10% in some
European studies using itraconazole.8,18 The outcome ismost likely
related to the severity of comorbid illnesses, the extent of
underlying pulmonary disease, and delays in diagnosis and the
initiation of effective therapy. In our study, the all-cause mortality
was 51%, and the median survival time was only 62 months.In conclusion, this study provides valuable information on the
difﬁculty in treating CNPA. Some recent studies have suggested
that voriconazole is an effective treatment for CNPA, with
acceptable toxicity.7,10,19 Further studies with more patients are
needed to identify the optimal therapy for patients with CNPA.
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